Thus, our secondary transplantation assays show that either spleen or bone marrow cells from mice with myeloid neoplasia due to shRNA-mediated reduced Mybl2 expression can efficiently transmit the blood disorder to secondary recipients. Here, MYBL2 is linked to hematologic disorder.